| Trial ID: | L3201 |
| Source ID: | NCT00388986
|
| Associated Drug: |
Gk Activator (2)
|
| Title: |
A Drug-Drug Interaction Study of GK Activator (2) and Glyburide in Patients With Type 2 Diabetes.
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus Type 2
|
| Interventions: |
DRUG: GK Activator (2)|DRUG: Glyburide
|
| Outcome Measures: |
Primary: AUC0-6h of plasma glucose, Days -1, 6 and 12|AUC0-12h of GK Activator (2) and metabolite., Days 6 and 12|AUC0-tau of glyburide, Days -1 and 6 | Secondary: AEs, laboratory parameters., Throughout study
|
| Sponsor/Collaborators: |
Sponsor: Hoffmann-La Roche
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
18
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: CROSSOVER|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2006-10
|
| Completion Date: |
2007-07
|
| Results First Posted: |
|
| Last Update Posted: |
2016-11-02
|
| Locations: |
Cypress, California, 90630, United States|Honolulu, Hawaii, 96813, United States|Buffalo, New York, NY 14215, United States|San Antonio, Texas, 78229, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00388986
|
